Search results

1656 results

Sorted by Relevance . Sort by Date

  1. Caesarean section (update)

    In development [GID-NG10081] Expected publication date: 31 March 2021

  2. Inducing labour (update)

    In development [GID-NG10082] Expected publication date: 14 October 2021

  3. Antenatal care

    In development [GID-NG10096] Expected publication date: 11 August 2021

  4. Postnatal care

    In development [GID-NG10070] Expected publication date: 07 April 2021

  5. Acne Vulgaris: Management

    In development [GID-NG10109] Expected publication date: 09 June 2021

  6. Diabetes update

    In development [GID-NG10152] Expected publication date: TBC

  7. Pernicious anaemia

    In development [GID-NG10176] Expected publication date: 23 March 2023

  8. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

    Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in

  9. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

  10. Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

    Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults

  11. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)

    Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)

  12. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

  13. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults